Methods for reducing exogenous insulin use

HK40135811APending Publication Date: 2026-07-31PROVENTION BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125076
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-30
Filing Date
2026-06-22
Publication Date
2026-07-31

Smart Images

  • Figure 00000058_0000
    Figure 00000058_0000
  • Figure 00000058_0001
    Figure 00000058_0001
  • Figure 00000058_0002
    Figure 00000058_0002
Patent Text Reader

Abstract

Provided herein are a method of reducing exogenous insulin use. In some embodiments, such method can include administering to a subject in need thereof a 12-day to 14-day course of teplizumab at a total dose of from about 9000 μg / m2 and about 14000 μg / m2.
Need to check novelty before this filing date? Find Prior Art

Description

This article provides a method for reducing exogenous insulin use. In some embodiments, such a method may include administering telizumab to a subject in need for a 12- to 14-day course at a total dose of about 9000 μg / m² to about 14000 μg / m². Abstract

Claims

CLAIMS1. A method of reducing exogenous insulin use in a subject in need thereof, the method comprising administering to the subject a 12-day to 14-day course of teplizumab at a total dose of from about 9000 pg / m2and about 14000 pg / m2, wherein administration of teplizumab results in a reduction of exogenous insulin use by at least 0.08 U / kg / day.

2. The method of claim 1, wherein administration of teplizumab results in a reduction of exogenous insulin use by at least 0.08 U / kg / day at year 1.

3. The method of claim 1, wherein administration of teplizumab results in a reduction of exogenous insulin use by at least 0.10 U / kg / day at year 2.

4. The method of claim 1, comprising administering to the subject a 12-day course of teplizumab.

5. The method of claim 4, wherein the 12-day course of teplizumab comprises: a first dose of about 106 pg / m2teplizumab on day 1, a second dose of about 425 pg / m2teplizumab on day 2, and one dose of about 850 pg / m2teplizumab on each of days 3-12.

6. The method of claim 1, comprising administering to the subject a 14-day course of teplizumab.

7. The method of claim 6, wherein the 14-day course of teplizumab comprises: a first dose of about 100 pg / m2teplizumab on day 1, a second dose of about 425 pg / m2teplizumab on day 2, a third dose of about 850 pg / m2teplizumab on day 3, a four dose of about 850 pg / m2teplizumab on day 4, and a dose of about 1000 pg / m2teplizumab on each of days 5-14.

8. The method of any one of claims 1-7, comprising administering a first and a second 12-day to 14-day courses of teplizumab.

9. The method of any one of claims 1-7, comprising administering a first and a second12-day courses of teplizumab.

10. The method of claim 8 or 9, wherein the two courses of teplizumab are administered at an interval of about 6 months.

11. The method of any one of claims 1-10, wherein the subject in need thereof has stage 3 type 1 diabetes.

12. The method of any one of claims 1-11, comprising administering teplizumab by intravenous infusion.

13. The method of any one of claims 1-12, wherein the subject in need thereof is about 7.5 years old or older.

14. The method of any one of claims 1-13, wherein reduction of exogenous insulin use is over a period of one year or more.

15. Teplizumab for use in reducing exogenous insulin use in a subject in need thereof in a method of any one of claims 1-14.

16. Use of teplizumab for the manufacture of a medicament for reducing exogenous insulin use in a subject in need thereof in a method of any one of claims 1-14.